Free Trial

ResMed (RMD) Stock Forecast & Price Target

ResMed logo
$256.71 +0.30 (+0.12%)
Closing price 03:59 PM Eastern
Extended Trading
$248.90 -7.80 (-3.04%)
As of 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
4
Buy
9

Based on 14 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 1 has given a sell rating, 4 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for RMD.

Consensus Price Target

$259.33
1.02% Upside
According to the 14 analysts' twelve-month price targets for ResMed, the average price target is $259.33. The highest price target for RMD is $290.00, while the lowest price target for RMD is $180.00. The average price target represents a forecasted upside of 1.02% from the current price of $256.71.
Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

Sign Up

RMD Analyst Ratings Over Time

TypeCurrent Forecast
7/8/24 to 7/8/25
1 Month Ago
6/8/24 to 6/8/25
3 Months Ago
4/9/24 to 4/9/25
1 Year Ago
7/9/23 to 7/8/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
4 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$259.33$259.33$249.73$202.80
Forecasted Upside1.02% Upside2.80% Upside15.24% Upside5.15% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ResMed Stock vs. The Competition

TypeResMedMedical CompaniesS&P 500
Consensus Rating Score
2.64
2.80
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside1.02% Upside9,181.37% Upside10.40% Upside
News Sentiment Rating
Positive News

See Recent RMD News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/20/2025Morgan Stanley
3 of 5 stars
David Bailey
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set TargetOverweight ➝ Overweight$286.00+16.50%
4/24/2025KeyCorp
3 of 5 stars
Brett Fishbin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$274.00+18.04%
4/24/2025Royal Bank Of Canada
4 of 5 stars
Craig Wong-Pan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSector Perform ➝ Sector Perform$247.00 ➝ $255.00+6.64%
4/24/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Sutcliffe
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$290.00 ➝ $285.00+19.36%
4/24/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Low
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$286.00 ➝ $290.00+22.49%
4/24/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Maeder
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$260.00 ➝ $248.00+5.20%
4/16/2025Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Anthony Petrone
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$265.00+25.12%
3/5/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mathieu Chevrier
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
3/5/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jonathan Block
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetHold ➝ Hold$250.00 ➝ $240.00+8.46%
1/31/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Matson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
1/16/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Thillainathan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
10/25/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$280.00 ➝ $283.00+18.39%
9/26/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$240.00 ➝ $270.00+11.12%
9/24/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Rescott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/18/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Polark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingPeer Perform ➝ Underperform$180.00-28.25%
6/25/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
10/5/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$240.00 ➝ $165.00+11.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:24 PM ET.


Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 6, 2025. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in ResMed Inc.:

  • The current stock price is around $246, which reflects a strong performance in the medical equipment sector.
  • ResMed Inc. reported a quarterly earnings per share (EPS) of $2.37, exceeding analysts' expectations, indicating robust financial health and effective management.
  • The company has shown a year-over-year revenue growth of 7.9%, suggesting a positive trend in sales and market demand for its products.
  • With a net margin of 26.15%, ResMed Inc. demonstrates strong profitability, which is attractive for investors looking for companies with solid earnings potential.
  • The company maintains a low debt-to-equity ratio of 0.12, indicating a conservative approach to leverage and financial stability, which can be reassuring for investors.

ResMed
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in ResMed Inc. for these reasons:

  • The dividend yield is relatively low at 0.83%, which may not attract income-focused investors looking for higher returns from dividends.
  • Despite strong earnings, the company's payout ratio is 23.79%, which may limit future dividend increases and could be a concern for dividend investors.
  • ResMed Inc. operates in a competitive healthcare market, which could pose risks to maintaining its market share and profitability in the long term.
  • Market volatility can impact stock performance, and any downturn in the healthcare sector could adversely affect ResMed Inc.'s stock price.
  • Investors may be cautious due to potential regulatory changes in the healthcare industry that could affect the company's operations and profitability.

RMD Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $259.33, with a high forecast of $290.00 and a low forecast of $180.00.

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There is currently 1 sell rating, 4 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RMD shares.

According to analysts, ResMed's stock has a predicted upside of 1.02% based on their 12-month stock forecasts.

ResMed has been rated by research analysts at JPMorgan Chase & Co., KeyCorp, Mizuho, Morgan Stanley, Piper Sandler, Royal Bank Of Canada, and UBS Group in the past 90 days.

Analysts like ResMed less than other "medical" companies. The consensus rating score for ResMed is 2.64 while the average consensus rating score for "medical" companies is 2.80. Learn more on how RMD compares to other companies.


This page (NYSE:RMD) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners